ClinicalTrials.Veeva

Menu

A Study Collecting Health Information to Understand and Prevent Gastric Cancer

Memorial Sloan Kettering Cancer Center (MSK) logo

Memorial Sloan Kettering Cancer Center (MSK)

Status

Enrolling

Conditions

Dysplasia
Gastric Cancer
Gastric Atrophy
Gastric Intestinal Metaplasia
Gastric Adenocarcinoma

Treatments

Behavioral: Questionnaire

Study type

Observational

Funder types

Other

Identifiers

Details and patient eligibility

About

The purpose of this study is to create a registry of participants with precursor lesions for gastric cancer, including gastric atrophy, intestinal metaplasia, and dysplasia. Normal controls and individuals with gastric cancer for comparison of baseline characteristics will also be enrolled.

Enrollment

3,200 estimated patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Age ≥ 18 years old

  • Able to read and understand English

  • Meet criteria for one of three potentially eligible study populations:

    • Individuals with gastric atrophy, gastric intestinal metaplasia, or dysplasia (increased risk): Had a previous diagnosis of or have been diagnosed by the investigation team with gastric atrophy, gastric intestinal metaplasia, or dysplasia of the gastric mucosa on pathology review from an endoscopic biopsy. Individuals who have a prior history of early gastric cancer may be included, if they were treated endoscopically and have no evidence of disease. Individuals who have a prior history of a cancer other than upper gastrointestinal cancer may also be included, if they have no evidence of disease for at least 1 year prior to study enrollment and are not undergoing active treatment for any malignancy at any time throughout the study period.
    • Healthy controls (average risk): Individuals with no history of cancer or gastric precursor lesions undergoing a clinically indicated endoscopy at MSK for workup or dyspepsia or reflux
    • Gastric cancer cases: Individuals with a known diagnosis of early gastric adenocarcinoma undergoing surgical resection at MSK

Exclusion criteria

  • Age < 18 years old
  • Women who are pregnant (may be enrolled after delivery)
  • Individuals with a prior history of upper gastrointestinal surgery or a prior cancer who are undergoing active treatment for malignancy or have been diagnosed within 1 year prior to the study enrollment. (This does not include incidentally diagnosed primary gastric adenocarcinoma identified during study follow up. Individuals diagnosed with gastric carcinoid limited to the stomach will also be included, given their ongoing parallel risk for gastric adenocarcinoma.)
  • Have severe comorbidities with expected survival time <2 years or which would prevent them from undergoing routine elective EGD (at the discretion of the patient's provider and the study team)

Trial design

3,200 participants in 3 patient groups

Participants with atrophic gastritis, intestinal metaplasia, and dysplasia
Description:
Participants with presence of atrophic gastritis, intestinal metaplasia, and dysplasia and risk of the progression of these lesions
Treatment:
Behavioral: Questionnaire
Control Group
Description:
Healthy controls
Treatment:
Behavioral: Questionnaire
Participants with gastric cancer
Description:
Participants with gastric cancer
Treatment:
Behavioral: Questionnaire

Trial contacts and locations

7

Loading...

Central trial contact

Xiang Shu, PhD; Monika Laszkowska, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems